🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

126 results for “pembrolizumab” Clear

  1. PACLITAXEL, CISPLATIN, CARBOPLATIN, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, PEMETREXED, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  2. PACLITAXEL, PF-08634404, SODIUM CHLORIDE, PACLITAXEL ALBUMIN-BOUND, PEMBROLIZUMAB, CARBOPLATIN, PEMETREXED

    Pfizer Ireland Pharmaceuticals Unlimited Company

    LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

    phase 3 small molecule active

    1 trial

  3. PEMBROLIZUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Squamous cell carcinoma of head and neck

    phase 3 small molecule active

    1 trial

  4. PEMBROLIZUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.

    phase 3 small molecule active

    1 trial

  5. PEMBROLIZUMAB , Adagloxad simolenin with adjuvant, CAPECITABINE

    Pharma Mar S.A.

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  6. PEMBROLIZUMAB , BNT113

    BioNTech Manufacturing GmbH

    Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer

    phase 3 small molecule active

    1 trial

  7. PEMBROLIZUMAB , IMFINZI 50 mg/mL concentrate for solution for infusion., JZP598, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Jazz Pharmaceuticals Ireland Limited

    BTC - Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  8. PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  9. PEMBROLIZUMAB , Placebo to match ly, ENFORTUMAB VEDOTIN

    Eli Lilly Co.

    Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  10. PEMBROLIZUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN, INFLIXIMAB, PACLITAXEL, MYCOPHENOLATE MOFETIL, GEMCITABINE, Datopotamab deruxtecan, PACLITAXEL ALBUMIN-BOUND

    AstraZeneca AB

    Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  11. PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN , PACLITAXEL , pembrolizumab, CISPLATIN

    Merck Sharp and Dohme

    Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial

  13. PEMETREXED, PALONOSETRON, Adagrasib, PEMBROLIZUMAB, CARBOPLATIN, tablets, CISPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Locally Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  14. PEMETREXED, PEMBROLIZUMAB, CISPLATIN, PACLITAXEL, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Cancer Prevention Pharma (Ireland) Limited

    Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line

    phase 3 small molecule active

    1 trial

  15. Pembrolizumab

    First Tracks Biotherapeutics

    Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  16. Pembrolizumab 25 MG/ML [Keytruda]

    United Therapeutics Europe Ltd

    Lung Cancer, Nonsmall Cell

    phase 3 small molecule active

    1 trial

  17. Placebo for pembrolizumab, ENZALUTAMIDE , PEMBROLIZUMAB

    Merck Sharp and Dohme

    Metastatic hormone sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  18. Placebo for pembrolizumab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , FLUOROURACIL , OXALIPLATIN , CISPLATIN

    Merck Sharp and Dohme

    Gastric and gastric esophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  19. Placebo to Pembrolizumab, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Locally Advanced Cervical Cancer

    phase 3 small molecule active

    1 trial

  20. Placebo to match LY, PEMBROLIZUMAB , DURVALUMAB

    Eli Lilly Co.

    Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  21. Placebo to match LY3537982, PEMBROLIZUMAB , PEMETREXED , CARBOPLATIN , CISPLATIN

    Eli Lilly Co.

    Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  22. QL2107, PEMBROLIZUMAB

    Pharma Mar S.A.

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  23. Rilvegostomig, DS-8201a, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CARBOPLATIN, DOCETAXEL, PACLITAXEL

    AstraZeneca AB

    HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  24. SELPERCATINIB, CARBOPLATIN , SELPERCATINIB, PEMBROLIZUMAB, CISPLATIN , PEMETREXED

    Eli Lilly Co.

    Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources